NPI: 1821061300 · BIRMINGHAM, AL 35233 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 02/07/2006
Authorized official WEY, SAMUEL controls 20+ related entities in our dataset. Read more
| Authorized Official | WEY, SAMUEL (VP LICENSURE & CERTIFICATION) |
| NPI Enumeration Date | 02/07/2006 |
Other providers sharing the same authorized official: WEY, SAMUEL
| Provider | City | State | Total Paid |
|---|---|---|---|
| DVA HEALTHCARE RENAL CARE INC | NORTH HOLLYWOOD | CA | $16.47M |
| DVA HEALTHCARE RENAL CARE INC | DELANO | CA | $16.43M |
| DVA RENAL HEALTHCARE INC | LOS ANGELES | CA | $15.51M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $14.93M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.67M |
| DVA RENAL HEALTHCARE INC | OAKLAND | CA | $13.42M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.25M |
| DVA HEALTHCARE RENAL CARE INC | YUMA | AZ | $12.88M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $12.77M |
| DVA RENAL HEALTHCARE INC | FULLERTON | CA | $12.19M |
| DVA HEALTHCARE RENAL CARE INC | POMONA | CA | $11.96M |
| DVA RENAL HEALTHCARE INC | ANAHEIM | CA | $11.32M |
| DVA RENAL HEALTHCARE INC | ESCONDIDO | CA | $10.94M |
| DVA HEALTHCARE RENAL CARE INC | COSTA MESA | CA | $10.08M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $9.46M |
| DVA RENAL HEALTHCARE INC | VISALIA | CA | $9.22M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $8.83M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $8.56M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $7.78M |
| DVA RENAL HEALTHCARE INC | PALM SPRINGS | CA | $7.48M |
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 19,963 | $376K |
| 2019 | 15,801 | $363K |
| 2020 | 12,379 | $193K |
| 2021 | 3,858 | $94K |
| 2022 | 1,162 | $42K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 16,722 | 1,218 | $631K |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 16,887 | 875 | $390K |
| J1756 | Injection, iron sucrose, 1 mg | 3,878 | 500 | $28K |
| 83970 | 615 | 502 | $7K | |
| J1270 | Injection, doxercalciferol, 1 mcg | 10,245 | 731 | $3K |
| A4657 | Syringe, with or without needle, each | 1,022 | 820 | $2K |
| 82108 | 129 | 104 | $1K | |
| 83550 | 459 | 379 | $1K | |
| 82728 | 470 | 375 | $964.06 | |
| 83540 | 457 | 378 | $664.78 | |
| 85041 | 733 | 613 | $568.23 | |
| 85048 | 733 | 613 | $528.75 | |
| 87340 | 87 | 23 | $228.30 | |
| 90674 | 39 | 32 | $192.40 | |
| 86706 | 73 | 24 | $189.15 | |
| 85045 | 218 | 178 | $159.30 | |
| 82607 | 13 | 12 | $75.36 | |
| 82746 | 14 | 13 | $72.30 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 355 | 217 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 14 | 13 | $0.00 |